Original R
esearch Article
Comparative Bioequivalence Assessment of Aspirin Tablets
Marketed in Nigeria
Emmanuel A Bamigbola1*, Musa A Ibrahim2,
Anthony A Attama3 and John E Arute4
1Department
of Pharmaceutics and Pharmaceutical Microbiology,
Faculty of Pharmacy, Madonna University, Elele, Rivers
State, Nigeria.
2Department
of Pharmaceutics and Pharmaceutical Technology, Faculty
of Pharmaceutical Sciences, University of Jos, Plateau
State, Nigeria.
3Department
of Pharmaceutics, Faculty of Pharmaceutical Sciences,
University of Nigeria, Nsukka 410001, Enugu State,
Nigeria.
4Department
of Clinical Pharmacy and Pharmacy Practice, Faculty of
Pharmacy, Madonna University, Elele, Rivers State,
Nigeria.
*For Correspondence:
Email:
bamigbolae@yahoo.com
Received:
10-Mar-09 Revised:
15-Dec-09 Accepted:
20-Dec-09
International Journal of Health Research,
December
2009; 2(4):
375-379
Abstract
Purpose: In the last few years, aspirin has
become a life saver against cardiovascular accidents.
This investigation was carried out to determine
possible bioequivalence between regular aspirin and
soluble aspirin tablets marketed in Nigeria.
Methods: The in vivo bioavailability profiles of
three commercial brands of aspirin tablets and soluble
aspirin tablets were assessed in eight healthy subjects.
Pharmacokinetic parameters including amounts of aspirin
excreted up to 24h (E24h), maximum excretion
rate (dE/dt)max and time for maximum
excretion rate (Tmax) were compared for all
the brands.
Results: There was no significant difference (p >
0.05) in the maximum excretion rates among all the
brands but the amount of soluble aspirin excreted up to
24 hours was a significantly different (p< 0.05) from
one of the regular brands of aspirin. The soluble brand
had significantly lower Tmax (p < 0.05) than
all the three plain brands. There was no significant
inter-subject variation among the subjects that
participated in the study.
Conclusion: Bioinequivalence exists between some
regular aspirin and soluble aspirin marketed in Nigeria.
Keywords: Soluble aspirin, aspirin,
pharmacokinetic parameters, in vivo bioequivalence.
